Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Sales of Investments
Cash received from selling or redeeming investments.
Immatics N.V.NASDAQ: IMTX
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of €43.43M fell 85.9% year over year, behind the -50.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 58.4% from the prior quarter. Over 3 fiscal years it compounded at +246.5% a year.
Context
- Sales of investments amounted to 1094.3% of revenue in FY2025, up 892.5 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -85.9% toward the trailing-twelve-month pace of -50.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
EUR · from the cash flow
- Latest · FY2025
- 528.16M EUR
- Year-over-year change
- +68.0%
- 4-year CAGR
- +115.6%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 528.16M | +68.0% |
| FY2024 | 2024-12-31 | 314.44M | -24.2% |
| FY2023 | 2023-12-31 | 414.74M | +3167.0% |
| FY2022 | 2022-12-31 | 12.7M | -48.1% |
| FY2021 | 2021-12-31 | 24.45M | — |
Sales of Investments vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -50.0% is the 7th highest of 10, against a peer median of -36.1%.
- Sales of investments amounts to 757.1% of revenue for IMTX, versus a peer median of 285.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €10.31B EUR | -19.6% | +189.9% | 389.9% | |
| LTM Sep 2026 | $1.02B USD | -79.1% | +105.5% | 75.2% | |
| LTM Mar 2026 | $495.32M USD | +176.4% | +4.1% | 2291.8% | |
| LTM Mar 2026 | €282.39M EUR | -50.0% | +246.5% | 757.1% | |
| LTM Mar 2026 | $275.21M USD | -52.0% | -3.7% | 887777.4% | |
| LTM Mar 2026 | $249.82M USD | -36.1% | -13.3% | — | |
| LTM Mar 2026 | $194.21M USD | +230.8% | +921.3% | 285.2% | |
| LTM Mar 2026 | $125.25M USD | -43.8% | — | 1371.0% | |
| LTM Mar 2026 | $13.99M USD | +39.9% | — | 3.6% | |
| LTM Mar 2026 | $7.89M USD | -74.5% | -55.9% | 34.1% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding IMTX) | — | -36.1% | +4.1% | 285.2% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.34M) | 37.51M | (94.65M) | 15.22M | (188.69M) |
| Depreciation & Amortization | 5.26M | 6.97M | 7.23M | 12.23M | 11.91M |
| Deferred Income Tax | 11.15M | 4.52M | 0 | 6.13M | 0 |
| Stock-Based Compensation | 26.4M | 22.57M | 20.71M | 17.64M | 0 |
| Change in Working Capital | (31.7M) | 37.26M | 81.63M | (163.88M) | (42.23M) |
| Accounts Receivables | 569K | (429K) | (2.98M) | (1.76M) | (232.45K) |
| Inventory | 0 | 0 | (84.24M) | 0 | 0 |
| Accounts Payables | (31.78M) | 45.56M | 84.24M | 0 | (36.13M) |
| Other Working Capital | (483K) | (7.87M) | 84.61M | (162.11M) | (5.87M) |
| Other Non-Cash Items | 433K | (8.7M) | 3.31M | (45.37M) | 49.36M |
| Operating Cash Flow | (81.78M) | 100.13M | 18.23M | (158.03M) | (169.66M) |
| Capital Expenditures | (5.66M) | (6.22M) | (30.96M) | (16.48M) | (6.3M) |
| Acquisitions (Net) | 551K | (199.91M) | 0 | 0 | 0 |
| Purchases of Investments | (11.3M) | (216.32M) | (415.33M) | (450.35M) | (324.92M) |
| Sales of Investments | 24.45M | 12.7M | 414.74M | 314.44M | 528.16M |
| Other Investing Activities | (551K) | 199.96M | (8K) | (206K) | 0 |
| Investing Cash Flow | 7.49M | (209.79M) | (31.39M) | (152.39M) | 196.7M |
| Debt Repayment | (2.71M) | (2.84M) | (3.85M) | (2.01M) | 0 |
| Common Stock Issued | 94K | 134.48M | 90.4M | 343.01M | 96.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (7.93M) | (2.04M) | (21.31M) | (2.84M) |
| Financing Cash Flow | (2.61M) | 123.71M | 84.52M | 319.68M | 93.51M |
| Effect of Forex Changes | 2.37M | 1.48M | (1.4M) | 9.01M | 16.56M |
| Net Change in Cash | (74.54M) | 15.53M | 69.95M | 18.28M | 137.12M |
| Free Cash Flow | (87.44M) | 93.92M | (12.73M) | (174.51M) | (175.95M) |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.